Volume 7, Issue 1 pp. 61-64
Methods
Full Access

Chimeric probe-mediated ribonuclease protection assay for molecular diagnosis of mRNA deficiencies

Philippe Maillet

Philippe Maillet

CNRS URA 1171, Institut Pasteur de Lyon, 69365 Lyon Cedex 07, France; Fax: (33)-72-72-25-49

Search for more papers by this author
Jean Delaunay

Jean Delaunay

CNRS URA 1171, Institut Pasteur de Lyon, 69365 Lyon Cedex 07, France; Fax: (33)-72-72-25-49

Search for more papers by this author
Faouzi Baklouti

Corresponding Author

Faouzi Baklouti

CNRS URA 1171, Institut Pasteur de Lyon, 69365 Lyon Cedex 07, France; Fax: (33)-72-72-25-49

CNRS URA 1171, Institut Pasteur de Lyon, 69365 Lyon Cedex 07, France; Fax: (33)-72-72-25-49Search for more papers by this author

Abstract

Investigations throughout the last decade have established that cytoskeleton integrity ensures red cell deformability and mechanical stability, and that defects in one of the skeletal components usually result in more or less severe hemolytic anemias. Although a large number of molecular defects have been identified to date, many others still bypass fast and commonly used methods, such as SSCP and DGGE, mostly because of a subtle change in mRNA transcription level or a complex interaction leading to the loss of other components. We describe a ribonuclease protection assay based on a simultaneous quantification of two cytoskeletal transcripts, using a chimeric probe, emphasizing the value of a nonspecific bridging sequence, inserted between the two specific probe sequences. It is anticipated that this powerful and reliable procedure would be an additional tool in the methodology array used for screening cytoskeletal inherited abnormalities. © 1996 Wiley-Liss, Inc.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.